Evidence map›Paper›PMID 41832301›Full record

ArticleScientific reports2026

Accelerating supercritical pharmaceutical formulation via interpretable data-driven prediction of drug solubility.

El-Sayed Khafagy, Amr Selim Abu Lila, Mahboubeh Pishnamazi

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

El-Sayed KhafagyDepartment of Pharmaceutics, College of Pharmacy, Prince Sattam bin Abdulaziz University, Al-kharj, 11942, Saudi Arabia.
Amr Selim Abu LilaDepartment of Pharmaceutics, College of Pharmacy, University of Ha'il, Ha'il, 81442, Saudi Arabia.
Mahboubeh PishnamaziInstitute of Research and Development, Duy Tan University, Da Nang, Vietnam. mahboubehpishnamazi@duytan.edu.vn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug solubility in supercritical carbon dioxide (SC-CO2) plays a pivotal role in the development of particle engineering, drug loading, and solvent-free pharmaceutical formulations. However, experimental solubility determination in supercritical systems remains costly, time-consuming, and compound-specific. In this study, an interpretable data-driven framework is proposed to support pharmaceutical formulation scientists by accurately predicting drug solubility in SC-CO2 while elucidating the governing physicochemical factors. Multiple machine learning regressors, including Extreme Gradient Boosting and Support Vector Regression, were developed and further integrated into an ensemble strategy to enhance robustness and generalizability. Model performance was systematically optimized using bio-inspired metaheuristic algorithms, enabling efficient hyperparameter selection across complex, nonlinear search spaces. Beyond predictive accuracy, model interpretability was emphasized through sensitivity-based and amplitude-based feature analyses, revealing the dominant molecular descriptors and process conditions influencing solubility behavior. The results demonstrate that the proposed framework not only improves solubility prediction accuracy but also provides mechanistic insights relevant to drug selection, formulation feasibility, and supercritical processing design. This work establishes a practical computational tool for accelerating pharmaceutical development pipelines involving supercritical fluid technologies.

Indexed as

Chemistry, PharmaceuticalDrug CompoundingAlgorithmsBoosting Machine Learning AlgorithmsCarbon DioxideData AnalyticsMachine LearningPharmaceutical PreparationsPrediction AlgorithmsSolubilityCarbon DioxidePharmaceutical PreparationsData-Driven Drug DesignDrug Solubility ModelingMachine Learning in PharmaceuticsPharmaceutical Formulation

Identifiers

PMID41832301
PMCPMC13043671

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.